Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and ...
Trodelvy in locally advanced or metastatic urothelial cancer may provide another option for those whose disease progressed ...
News Medical on MSN2d
FORT-2 trial shows promising results for bladder cancer immunotherapy combinationIn urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. Previous clinical studies with an FGFR inhibitor, rogaratinib, demonstrated that the ...
Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients ...
A. Menarini Diagnostics, a company bringing advanced solutions to the in vitro diagnostic market, and Nucleix, a liquid ...
CG Oncology stock is up 7% following bladder cancer data released by Johnson & Johnson. Read more here.
Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thymic Carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback